Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Authors
Keywords
-
Journal
JOURNAL OF PSYCHOPHARMACOLOGY
Volume 30, Issue 3, Pages 227-236
Publisher
SAGE Publications
Online
2016-01-23
DOI
10.1177/0269881115625496
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment of clozapine-associated weight gain: a systematic review
- (2015) Z. Whitney et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
- (2015) Donna Ryan et al. Obesity
- Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
- (2015) Feng Sun et al. Journal of Diabetes Research
- GLP-1 based therapeutics: simultaneously combating T2DM and obesity
- (2015) Kristy M. Heppner et al. Frontiers in Neuroscience
- Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States
- (2014) Stephen S. Johnston et al. ADVANCES IN THERAPY
- Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials
- (2014) Matteo Monami et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Therapies for inter-relating diabetes and obesity – GLP-1 and obesity
- (2014) Eva W Iepsen et al. EXPERT OPINION ON PHARMACOTHERAPY
- Erratum: Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2014) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss
- (2014) E W Iepsen et al. INTERNATIONAL JOURNAL OF OBESITY
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
- (2014) Anna Secher et al. JOURNAL OF CLINICAL INVESTIGATION
- Glucometabolic Hormones and Cardiovascular Risk Markers in Antipsychotic-Treated Patients
- (2014) Bjørn H. Ebdrup et al. JOURNAL OF CLINICAL PSYCHIATRY
- A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society
- (2014) Jenny E Gunton et al. MEDICAL JOURNAL OF AUSTRALIA
- Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats
- (2014) Ajaykumar N. Sharma et al. METABOLIC BRAIN DISEASE
- Dipeptidyl-peptidase IV (DPP-IV) inhibitor delays tolerance to anxiolytic effect of ethanol and withdrawal-induced anxiety in rats
- (2014) Ajaykumar N. Sharma et al. METABOLIC BRAIN DISEASE
- GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats
- (2014) Ajaykumar N. Sharma et al. METABOLIC BRAIN DISEASE
- Genetic variation in theGCGand in theGLP1Rgenes and antipsychotic-induced weight gain
- (2014) Eva J Brandl et al. PHARMACOGENOMICS
- Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis
- (2014) Y. Mizuno et al. SCHIZOPHRENIA BULLETIN
- Clozapine directly increases insulin and glucagon secretion from islets: Implications for impairment of glucose tolerance
- (2014) G.C. Smith et al. SCHIZOPHRENIA RESEARCH
- Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol
- (2014) Pelle L Ishøy et al. BMJ Open
- Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial
- (2014) Julie Rask Larsen et al. BMJ Open
- Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials胰高血糖素样肽-1类似物对非糖尿病肥胖/超重成人的减重作用：一篇对随机对照试验进行的系统评价及meta分析
- (2014) Fang Zhang et al. Journal of Diabetes
- Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
- (2014) Kira B. Harris et al. Therapeutic Advances in Endocrinology and Metabolism
- GLP-1 receptor agonists: a review of head-to-head clinical studies
- (2014) Jennifer M. Trujillo et al. Therapeutic Advances in Endocrinology and Metabolism
- Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes
- (2013) Pelle L. Ishøy et al. AMERICAN JOURNAL OF PSYCHIATRY
- Effect of Antihyperglycemic Agents Added to Metformin and a Sulfonylurea on Glycemic Control and Weight Gain in Type 2 Diabetes: A Network Meta-analysis
- (2013) Jorge L. Gross ANNALS OF INTERNAL MEDICINE
- Antipsychotic-Induced Insulin Resistance and Postprandial Hormonal Dysregulation Independent of Weight Gain or Psychiatric Disease
- (2013) Karen L. Teff et al. DIABETES
- The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications
- (2013) S. Madsbad DIABETES OBESITY & METABOLISM
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis
- (2013) Tejashree S. Dixit et al. PHYSIOLOGY & BEHAVIOR
- The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice
- (2013) Emil Egecioglu et al. PLoS One
- The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers
- (2013) D. Lawrence et al. BMJ-British Medical Journal
- Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
- (2012) Bjørn H Ebdrup et al. BMC Medicine
- Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
- (2012) Aaron S Kelly et al. Cardiovascular Diabetology
- Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis
- (2012) C. F. Deacon et al. DIABETES OBESITY & METABOLISM
- Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis
- (2012) S.-C. Liu et al. DIABETES OBESITY & METABOLISM
- GLP-1 analog attenuates cocaine reward
- (2012) D L Graham et al. MOLECULAR PSYCHIATRY
- The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents
- (2012) Emil Egecioglu et al. PSYCHONEUROENDOCRINOLOGY
- Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials
- (2012) Jacqueline Caemmerer et al. SCHIZOPHRENIA RESEARCH
- A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia
- (2011) Jari Tiihonen et al. AMERICAN JOURNAL OF PSYCHIATRY
- Atypical Antipsychotic-Induced Weight Gain
- (2011) James L. Roerig et al. CNS DRUGS
- Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
- (2011) J. Dushay et al. DIABETES CARE
- Type-2 diabetes mellitus in schizophrenia: Increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up
- (2011) D. Schoepf et al. EUROPEAN PSYCHIATRY
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- Glucagon-Like Peptide 1 Receptors in Nucleus Accumbens Affect Food Intake
- (2011) A. M. Dossat et al. JOURNAL OF NEUROSCIENCE
- The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
- (2011) P. L. McClean et al. JOURNAL OF NEUROSCIENCE
- Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat
- (2011) G. C. Smith et al. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
- Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing
- (2010) Mark Fineman et al. CLINICAL PHARMACOKINETICS
- Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes
- (2010) J. Rosenstock et al. DIABETES CARE
- Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice
- (2010) Simon Gengler et al. NEUROBIOLOGY OF AGING
- Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis
- (2010) Lawrence Maayan et al. NEUROPSYCHOPHARMACOLOGY
- Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
- (2010) Christine Rummel-Kluge et al. SCHIZOPHRENIA RESEARCH
- Preclinical models of antipsychotic drug-induced metabolic side effects
- (2010) Heidi N. Boyda et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
- (2010) Deepson S Shyangdan et al. BMC Endocrine Disorders
- A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia
- (2009) D. C. Henderson et al. ACTA PSYCHIATRICA SCANDINAVICA
- Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily
- (2009) J. H. Best et al. DIABETIC MEDICINE
- Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets
- (2009) Solrun Vidarsdottir et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Effects of Olanzapine and Haloperidol on the Metabolic Status of Healthy Men
- (2009) Solrun Vidarsdottir et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
- (2009) Jari Tiihonen et al. LANCET
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: Implications for glucose metabolism and food choice behaviour
- (2009) Greg C. Smith et al. SCHIZOPHRENIA RESEARCH
- Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease
- (2008) B. Martin et al. DIABETES
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2008) D. M. Nathan et al. DIABETES CARE
- Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat
- (2008) G. C. Smith et al. DIABETOLOGIA
- Comparison of Single and Combined Treatment with Exenatide and Metformin on Menstrual Cyclicity in Overweight Women with Polycystic Ovary Syndrome
- (2008) Karen Elkind-Hirsch et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Modulation of taste sensitivity by GLP-1 signaling
- (2008) Yu-Kyong Shin et al. JOURNAL OF NEUROCHEMISTRY
- The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance
- (2008) Kirsten Lykkegaard et al. SCHIZOPHRENIA RESEARCH
- Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease
- (2007) Göran Bertilsson et al. JOURNAL OF NEUROSCIENCE RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started